In addition, NPAS2 has been identified as a prognostic biomarker in breast and colorectal cancers [42, 43], in which reduced NPAS2 expression was associated with decreased disease-free and overall survival rates in patients with breast cancer [43], in line with our present results in patients with prostate cancer. This evidence concerns the gene NPAS2 and breast carcinoma.